secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001108205-23-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study
--------------------------------------------------------------------------------

- Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).
- Revenue $2.2M from Erivedge royalties; R&D expense $10.0M (down 19% YoY), G&A $4.2M (down 18% YoY).
- FDA removed partial clinical hold on emavusertib TakeAim Leukemia study; confirmed RP2D at 300 mg BID.
- Cash, equivalents and investments $77.4M after July registered direct offering ($13.8M net); runway into 2025.
- Updated clinical data from monotherapy and combination studies expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/cris-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001108205-23-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer